Header Logo

Connection

SUSAN BLANEY to Adult

Back to Details
This is a "connection" page, showing publications SUSAN BLANEY has written about Adult.
SUSAN BLANEY
Connection Strength
0.737
Adult
  1. A phase 2 study of valproic acid and radiation, followed by maintenance valproic acid and bevacizumab in children with newly diagnosed diffuse intrinsic pontine glioma or high-grade glioma. Pediatr Blood Cancer. 2020 06; 67(6):e28283.
    View in: PubMed
    Score: 0.038
  2. Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADVL1411). Pediatr Blood Cancer. 2020 02; 67(2):e28073.
    View in: PubMed
    Score: 0.037
  3. A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra-cranial solid tumors: a Children's Oncology Group Phase I Consortium report. Pediatr Blood Cancer. 2015 May; 62(5):751-8.
    View in: PubMed
    Score: 0.027
  4. A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Report. Clin Cancer Res. 2015 Apr 01; 21(7):1558-65.
    View in: PubMed
    Score: 0.026
  5. Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2015 Mar; 62(3):440-4.
    View in: PubMed
    Score: 0.026
  6. Phase I trial of Seneca Valley Virus (NTX-010) in children with relapsed/refractory solid tumors: a report of the Children's Oncology Group. Pediatr Blood Cancer. 2015 May; 62(5):743-50.
    View in: PubMed
    Score: 0.026
  7. A phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: a pediatric brain tumor consortium report. Neuro Oncol. 2014 Dec; 16(12):1661-8.
    View in: PubMed
    Score: 0.025
  8. Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2014 Mar; 61(3):452-6.
    View in: PubMed
    Score: 0.024
  9. Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children's oncology group phase I consortium report. J Clin Oncol. 2013 Aug 20; 31(24):3034-43.
    View in: PubMed
    Score: 0.024
  10. Phase I trial of capecitabine rapidly disintegrating tablets and concomitant radiation therapy in children with newly diagnosed brainstem gliomas and high-grade gliomas. Neuro Oncol. 2013 Jun; 15(6):759-66.
    View in: PubMed
    Score: 0.024
  11. A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study. Pediatr Blood Cancer. 2013 Sep; 60(9):1452-7.
    View in: PubMed
    Score: 0.023
  12. Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol. 2012 Jan 20; 30(3):256-62.
    View in: PubMed
    Score: 0.021
  13. A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: a report from the Children's Oncology Group. Eur J Cancer. 2012 Mar; 48(4):579-85.
    View in: PubMed
    Score: 0.021
  14. Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study. Clin Cancer Res. 2011 Aug 01; 17(15):5113-22.
    View in: PubMed
    Score: 0.021
  15. Reasons for participation in optional pharmacokinetic studies in children with cancer: a Children's Oncology Group phase 1 consortium study. Pediatr Blood Cancer. 2010 Jul 15; 55(1):119-22.
    View in: PubMed
    Score: 0.019
  16. Phase 1 study of oxaliplatin and irinotecan in pediatric patients with refractory solid tumors: a children's oncology group study. Cancer. 2009 Apr 15; 115(8):1765-75.
    View in: PubMed
    Score: 0.018
  17. Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol. 2007 Oct 10; 25(29):4622-7.
    View in: PubMed
    Score: 0.016
  18. Phase I clinical trial of intrathecal gemcitabine in patients with neoplastic meningitis. Cancer Chemother Pharmacol. 2008 Jul; 62(2):355-61.
    View in: PubMed
    Score: 0.016
  19. Phase I trial of irofulven (MGI 114) in pediatric patients with solid tumors. Pediatr Blood Cancer. 2006 Aug; 47(2):163-8.
    View in: PubMed
    Score: 0.015
  20. Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children's Oncology Group report. J Clin Oncol. 2006 Aug 01; 24(22):3678-85.
    View in: PubMed
    Score: 0.015
  21. A phase I study of irinotecan administered on a weekly schedule in pediatric patients. Pediatr Blood Cancer. 2006 Jan; 46(1):50-5.
    View in: PubMed
    Score: 0.014
  22. Phase I trial of intrathecal liposomal cytarabine in children with neoplastic meningitis. J Clin Oncol. 2004 Oct 01; 22(19):3916-21.
    View in: PubMed
    Score: 0.013
  23. Pharmacokinetics of phenylacetate administered as a 30-min infusion in children with refractory cancer. Cancer Chemother Pharmacol. 2003 Nov; 52(5):417-23.
    View in: PubMed
    Score: 0.012
  24. Phase I clinical trial of intrathecal topotecan in patients with neoplastic meningitis. J Clin Oncol. 2003 Jan 01; 21(1):143-7.
    View in: PubMed
    Score: 0.012
  25. A phase I study of irinotecan in pediatric patients: a pediatric oncology group study. Clin Cancer Res. 2001 Jan; 7(1):32-7.
    View in: PubMed
    Score: 0.010
  26. Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study. Clin Cancer Res. 1998 Feb; 4(2):357-60.
    View in: PubMed
    Score: 0.008
  27. Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2018 03; 65(3).
    View in: PubMed
    Score: 0.008
  28. A phase 1 study of the c-Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111). Pediatr Blood Cancer. 2017 Nov; 64(11).
    View in: PubMed
    Score: 0.008
  29. Phase I trial of docetaxel administered as a 1-hour infusion in children with refractory solid tumors: a collaborative pediatric branch, National Cancer Institute and Children's Cancer Group trial. J Clin Oncol. 1997 Apr; 15(4):1538-43.
    View in: PubMed
    Score: 0.008
  30. First-dose and steady-state pharmacokinetics of orally administered crizotinib in children with solid tumors: a report on ADVL0912 from the Children's Oncology Group Phase 1/Pilot Consortium. Cancer Chemother Pharmacol. 2017 Jan; 79(1):181-187.
    View in: PubMed
    Score: 0.008
  31. Phase II evaluation of topotecan for pediatric central nervous system tumors. Cancer. 1996 Aug 01; 78(3):527-31.
    View in: PubMed
    Score: 0.007
  32. Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas. Pediatr Blood Cancer. 2014 Sep; 61(9):1598-602.
    View in: PubMed
    Score: 0.006
  33. Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion. Cancer Res. 1993 Mar 01; 53(5):1032-6.
    View in: PubMed
    Score: 0.006
  34. Current pharmacological treatment approaches to central nervous system leukaemia. Drugs. 1991 May; 41(5):702-16.
    View in: PubMed
    Score: 0.005
  35. Pharmacologic approaches to the treatment of meningeal malignancy. Oncology (Williston Park). 1991 May; 5(5):107-16; discussion 123, 127.
    View in: PubMed
    Score: 0.005
  36. A phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent/refractory neuroblastoma: a new approaches to neuroblastoma therapy (NANT) study. Pediatr Blood Cancer. 2011 Aug; 57(2):275-82.
    View in: PubMed
    Score: 0.005
  37. Phase I study of decitabine with doxorubicin and cyclophosphamide in children with neuroblastoma and other solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer. 2010 Oct; 55(4):629-38.
    View in: PubMed
    Score: 0.005
  38. Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report. J Clin Oncol. 2010 Aug 01; 28(22):3623-9.
    View in: PubMed
    Score: 0.005
  39. Phase II trial of ixabepilone administered daily for five days in children and young adults with refractory solid tumors: a report from the children's oncology group. Clin Cancer Res. 2010 Jan 15; 16(2):750-4.
    View in: PubMed
    Score: 0.005
  40. Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study. J Clin Oncol. 2008 Oct 20; 26(30):4921-7.
    View in: PubMed
    Score: 0.004
  41. Motexafin gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: a Children's Oncology Group phase I study. Neuro Oncol. 2008 Oct; 10(5):752-8.
    View in: PubMed
    Score: 0.004
  42. Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study. J Clin Oncol. 2008 Aug 01; 26(22):3756-62.
    View in: PubMed
    Score: 0.004
  43. Characteristics and outcome of pediatric patients enrolled in phase I oncology trials. Oncologist. 2008 Jun; 13(6):679-89.
    View in: PubMed
    Score: 0.004
  44. A phase I trial of temozolomide and lomustine in newly diagnosed high-grade gliomas of childhood. Neuro Oncol. 2008 Aug; 10(4):569-76.
    View in: PubMed
    Score: 0.004
  45. A phase II trial of rebeccamycin analogue (NSC #655649) in children with solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer. 2008 Mar; 50(3):577-80.
    View in: PubMed
    Score: 0.004
  46. Pharmacokinetics of irinotecan and its metabolites in pediatric cancer patients: a report from the children's oncology group. Cancer Chemother Pharmacol. 2008 Nov; 62(6):1027-37.
    View in: PubMed
    Score: 0.004
  47. Phase I trial of VNP40101M (Cloretazine) in children with recurrent brain tumors: a pediatric brain tumor consortium study. Clin Cancer Res. 2008 Feb 15; 14(4):1124-30.
    View in: PubMed
    Score: 0.004
  48. A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer. 2008 Feb; 50(2):254-8.
    View in: PubMed
    Score: 0.004
  49. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol. 2008 Jan 20; 26(3):399-405.
    View in: PubMed
    Score: 0.004
  50. Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: a Children's Oncology Group Study. J Clin Oncol. 2007 Nov 01; 25(31):4922-8.
    View in: PubMed
    Score: 0.004
  51. Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma. Blood. 2008 Jan 15; 111(2):566-73.
    View in: PubMed
    Score: 0.004
  52. Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium Study. J Clin Oncol. 2007 Jul 20; 25(21):3137-43.
    View in: PubMed
    Score: 0.004
  53. A phase I study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: a Children's Oncology Group study. Clin Cancer Res. 2007 Mar 15; 13(6):1789-93.
    View in: PubMed
    Score: 0.004
  54. Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report. Neuro Oncol. 2007 Apr; 9(2):145-60.
    View in: PubMed
    Score: 0.004
  55. Topotecan by 21-day continuous infusion in children with relapsed or refractory solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer. 2006 Nov; 47(6):790-4.
    View in: PubMed
    Score: 0.004
  56. A phase II window trial of procarbazine and topotecan in children with high-grade glioma: a report from the children's oncology group. J Neurooncol. 2006 Apr; 77(2):193-8.
    View in: PubMed
    Score: 0.004
  57. Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004). Clin Cancer Res. 2006 Mar 01; 12(5):1540-6.
    View in: PubMed
    Score: 0.004
  58. Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol. 2005 Sep 01; 23(25):6172-80.
    View in: PubMed
    Score: 0.003
  59. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group. J Clin Oncol. 2005 May 20; 23(15):3376-82.
    View in: PubMed
    Score: 0.003
  60. Phase I trial and pharmacokinetic study of raltitrexed in children with recurrent or refractory leukemia: a pediatric oncology group study. Clin Cancer Res. 2005 Mar 01; 11(5):1884-9.
    View in: PubMed
    Score: 0.003
  61. Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial. Leukemia. 2005 Jan; 19(1):34-8.
    View in: PubMed
    Score: 0.003
  62. Phase I and pharmacokinetic study of thalidomide with carboplatin in children with cancer. J Clin Oncol. 2004 Nov 01; 22(21):4394-400.
    View in: PubMed
    Score: 0.003
  63. Pharmacokinetics of O(6)-benzylguanine in pediatric patients with central nervous system tumors: a pediatric oncology group study. Clin Cancer Res. 2004 Aug 01; 10(15):5072-5.
    View in: PubMed
    Score: 0.003
  64. Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study. Blood. 2004 Nov 01; 104(9):2655-60.
    View in: PubMed
    Score: 0.003
  65. Phase I trial of tirapazamine and cyclophosphamide in children with refractory solid tumors: a pediatric oncology group study. J Clin Oncol. 2004 Apr 15; 22(8):1413-9.
    View in: PubMed
    Score: 0.003
  66. Pediatric phase I trial and pharmacokinetic study of the platelet-derived growth factor (PDGF) receptor pathway inhibitor SU101. Cancer Chemother Pharmacol. 2004 Jun; 53(6):482-8.
    View in: PubMed
    Score: 0.003
  67. Phase I clinical and pharmacologic study of weekly cisplatin and irinotecan combined with amifostine for refractory solid tumors. Clin Cancer Res. 2003 Feb; 9(2):703-10.
    View in: PubMed
    Score: 0.003
  68. Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: a pediatric oncology group study. Clin Cancer Res. 2002 Feb; 8(2):413-8.
    View in: PubMed
    Score: 0.003
  69. Phase II trial of pyrazoloacridine in children with solid tumors: a Pediatric Oncology Group phase II study. J Pediatr Hematol Oncol. 2000 Nov-Dec; 22(6):506-9.
    View in: PubMed
    Score: 0.002
  70. Phase I and pharmacokinetic study of CI-980 in recurrent pediatric solid tumor cases: a Pediatric Oncology Group study. J Pediatr Hematol Oncol. 1999 Nov-Dec; 21(6):494-500.
    View in: PubMed
    Score: 0.002
  71. Phase I trial of docetaxel with filgrastim support in pediatric patients with refractory solid tumors: a collaborative Pediatric Oncology Branch, National Cancer Institute and Children's Cancer Group trial. Clin Cancer Res. 1999 Apr; 5(4):733-7.
    View in: PubMed
    Score: 0.002
  72. Phase I trial of 9-aminocamptothecin in children with refractory solid tumors: a Pediatric Oncology Group study. J Clin Oncol. 1998 Jul; 16(7):2494-9.
    View in: PubMed
    Score: 0.002
  73. Phase I trial and pharmacokinetic study of pyrazoloacridine in children and young adults with refractory cancers. J Clin Oncol. 1998 Jan; 16(1):181-6.
    View in: PubMed
    Score: 0.002
  74. Phase I trial and pharmacokinetic study of all-trans-retinoic acid administered on an intermittent schedule in combination with interferon-alpha2a in pediatric patients with refractory cancer. J Clin Oncol. 1997 Nov; 15(11):3330-7.
    View in: PubMed
    Score: 0.002
  75. A prospective evaluation of ifosfamide-related nephrotoxicity in children and young adults. Cancer. 1995 Dec 15; 76(12):2557-64.
    View in: PubMed
    Score: 0.002
  76. A phase I trial of amifostine (WR-2721) and melphalan in children with refractory cancer. Cancer Res. 1995 Sep 15; 55(18):4069-72.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.